LLMC 2020 | Key BTK inhibitor trials for the initial treatment of CLL
Jenifer Woyach, MD, The Ohio State University, Columbus, OH, highlights key trials investigating BTK inhibitors versus chemoimmunotherapy as an initial treatment for chronic lymphocytic leukemia (CLL). Dr Woyach discusses the results of the Phase III E1912 study (NCT02048813), the Phase III Alliance study (NCT01886872) and the iLLUMINATE study (NCT02264574) which all found benefits to progression-free survival using ibrutinib plus rituximab or obinutuzumab treatment versus chemoimmunotherapy options. She also highlights two ongoing trials for CLL treatment in the frontline setting: the Phase III EA9161 trial (NCT03701282) and the Phase III A041702 trial (NCT03737981), both comparing ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consulting/advisory boards: Janssen, Pharmacyclics, Abbvie, AstraZeneca, Arqule
